Reversing methods of tumor multidrug resistance

doi:10.3760/cma.j.issn.1673422X.2016.05.011

Abstract

Abstract: Chemotherapy is one of the main treatment methods in malignant tumor. Tumor multidrug resistance (MDR) is one of the important reasons for the failure of chemotherapy. It makes some progress in reversing tumor MDR, such as chemical drug, traditional Chinese medicine, immunotherapy, gene therapy, nanoparticles drug system and so on. But it takes more effort to develop medicine of less adverse reactions, better pharmacodynamic and application to clinic widely.

Key words: Neoplasms, Drug therapy, Multidrug resistanceassociated proteins

Chen Ying, Zhang Xingping. Reversing methods of tumor multidrug resistance[J]. Journal of International Oncology, 2016, 43(5): 364-367.

References

［1］ Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of Pgp inhibitors: skimming through several generations and scaffolds［J］. Curr Med Chem, 2012, 19(13): 1946-2025. ［2］ Vadlapatla RK, Vadlapudi AD, Pal D, et al. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes［J］. Curr Pharm Des, 2013, 19(40): 7126-7140. ［3］ Wu Q, Yang Z, Nie Y, et al. Multidrug resistance in cancer chemotherapeutics: mechanisms and Lab approaches［J］. Cancer Lett, 2014, 347(2): 159-166. DOI: 10.1016/j.canlet.2014.03.013. ［4］ Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer［J］. Biotechnol Adv, 2013, 31(8): 1397-1407. DOI: 10.1016/j.biotechadv.2013.06.004. ［5］ Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice［J］. Oncologist, 2003, 8(5): 411-424. ［6］ Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 570-594. ［7］ Tang R, Faussat AM, Perrot JY, et al. Zosuquidar restores drug sensitivity in Pglycoprotein expressing acute myeloid leukemia (AML)［J］. BMC Cancer, 2008, 8(8): 51. DOI: 10.1186/14712407851. ［8］ Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of Pglycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebocontrolled trial of the Eastern Cooperative Oncology Group 3999［J］. Blood, 2010, 116(20): 4077-4085. DOI: 10.1182/blood201004277269. ［9］ Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 609-620. ［10］袁斐, 白钢钢, 苗筠杰, 等. 中药逆转肿瘤细胞多药耐药的研究进展［J］. 中草药, 2014, 45(6): 857-863. DOI: 10.7501/j.issn.02532670.2014.06.023. ［11］ Lu WD, Qin Y, Yang C, et al. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo［J］. Clinics (Sao Paulo), 2013, 68(5): 694-701. DOI: 10.6061/clinics/2013(05)18. ［12］ Guo H, Jiang W, Liu W, et al. Extracellular domain of 41BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by antiCD3 x antiPgp bispecific diabody against human multidrugresistant leukemia［J］. Cell Immunol, 2008, 251(2): 102-108. DOI: 10.1016/j.cellimm.2008.04.006. ［13］ Grodzovski I, Lichtenstein M, Galski H, et al. IL2granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3independent apoptotic pathway［J］. Int J Cancer, 2011, 128(8): 1966-1980. DOI: 10.1002/ijc.25527. ［14］ Mizukoshi E, Nakagawa H, Kitahara M, et al. Phase Ⅰ trial of multidrug resistanceassociated protein 3derived peptide in patients with hepatocellular carcinoma［J］. Cancer Lett, 2015, 369(1): 242-249. DOI: 10.1016/ j.canlet.2015.08.020. ［15］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line［J］. DNA Cell Biol, 2011, 30(6): 413-418. DOI: 10.1089/dna.2010.1143. ［16］揭惠, 酉明巧, 刘辉, 等. 肿瘤多药耐药的发生机制及逆转策略［J］. 中华中医药学刊, 2013 (7): 1686-1690. ［17］ Binkhathlan Z, Lavasanifar A. Pglycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives［J］. Curr Cancer Drug Targets, 2013, 13(3): 326-346. ［18］ Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)［J］. FEBS Lett, 2003, 545(2/3): 144-150. ［19］ Li JM, Zhang W, Su H, et al. Reversal of multidrug resistance in MCF7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acidconjugated polyethylenimine hydroxypropylβcyclodextrin nanocarrier［J］. Int J Nanomedicine, 2015, 10: 3147-3162. DOI: 10.2147/IJN.S67146. ［20］ Tian W, Chen J, He H, et al. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications［J］. Clin Transl Oncol, 2013, 15(5): 335-342. DOI: 10.1007/s1209401209295. ［21］ Hu Y, Xu K, Yagüe E. miR218 targets survivin and regulates resistance to chemotherapeutics in breast cancer［J］. Breast Cancer Res Treat, 2015, 151(2): 269-280. DOI: 10.1007/s1054901533729. ［22］ Milane L, Ganesh S, Shah S, et al. Multimodal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology［J］. J Control Release, 2011, 155(2): 237-247. DOI: 10.1016/j.jconrel.2011.03.032. ［23］ He Q, Shi J. MSN anticancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition［J］. Adv Mater, 2014, 26(3): 391-411. DOI: 10.1002/adma.201303123. ［24］贾晋斌, 韦青燕. 阿霉素脂质体的研究进展［J］. 中国肿瘤, 2011, 20(5): 372-377. DOI: 10.1063/1.3253351. ［25］ Huang C, Li Y, Cao P, et al. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycinresistant SGC7901/ADM gastric cancer cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 488-496. DOI: 10.1007/s1159601104780. ［26］ Mao Z, Zhou J, Luan J, et al. Tamoxifen reduces Pgpmediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ERnegative human gastric cancer cells［J］. Biomedicine Pharmacother, 2014, 68(2): 179-183. DOI: 10.1016/j.biopha.2013.10.003.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.